IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,510 shares of the company’s stock after selling 256 shares during the quarter. Kintegral Advisory LLC’s holdings in IDEXX Laboratories were worth $2,278,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the third quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $31,000. Ashton Thomas Securities LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $37,000. Finally, Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.0 %

NASDAQ:IDXX opened at $452.77 on Friday. The firm has a market capitalization of $37.08 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average of $431.92 and a 200-day moving average of $452.28.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Barclays upped their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock worth $6,161,276 in the last three months. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.